Tscan therapeutics appoints debora barton, m.d., as chief medical officer

Waltham, mass., july 07, 2022 (globe newswire) -- tscan therapeutics, inc. (nasdaq: tcrx), a clinical-stage biopharmaceutical company focused on the development of t-cell receptor (tcr) engineered t cell therapies (tcr-t) for the treatment of patients with cancer, today announced the appointment of debora barton, m.d., as chief medical officer. dr. barton, a clinical oncologist experienced in developing cell therapies for cancers, brings to tscan nearly two decades of expertise across global clinical research and development, and executive leadership in large pharma and midsized and small biotech companies.
TCRX Ratings Summary
TCRX Quant Ranking